The Indian Institute of Technology (IIT) Bombay has partnered with QR678 through its translational arm TECCRO. The collaboration will advance research in dermatology, trichology, and regenerative medicine.
Focus on evidence-based dermatology
Both parties signed a formal Memorandum of Understanding to drive scientific innovation. They will focus on evidence-based treatments for skin and hair disorders. The partnership integrates engineering science with clinical dermatology expertise.
IIT Bombay will contribute strengths in biomaterials and biomedical engineering. Its faculty will also support biosciences, computational research, and translational modelling. TECCRO will provide clinical research infrastructure and regulatory oversight. It will supervise structured trials under established ethical frameworks.
Advancing translational research
The QR678 platform will continue its research operations at the IIT Bombay campus. Researchers will gain access to advanced laboratories and technical facilities. They will design studies to evaluate regenerative healing mechanisms. The teams will prioritise scalable and reproducible treatment protocols.
The collaboration aims to accelerate translational research outcomes. Scientists will convert laboratory discoveries into clinical therapies. They will validate results through controlled clinical evaluations. The programme will emphasise measurable and peer-reviewed outcomes.
Both institutions plan to generate joint intellectual property. They will file patents for novel formulations and delivery technologies. Researchers will publish findings in national and international journals. The teams will also pursue competitive research grants.
Strengthening regenerative medicine in India
The alliance strengthens India’s position in regenerative dermatology research. It creates a structured bridge between academia and industry. The programme encourages multidisciplinary collaboration across medical and engineering domains.
Trichology research will examine hair growth biology and follicular regeneration. Dermatology research will explore advanced interventions for chronic skin conditions. Scientists will study molecular pathways involved in tissue repair. They will investigate biomaterial-based delivery systems for therapeutic agents.
Clinical teams will monitor safety, efficacy, and long-term outcomes. Researchers will document patient responses through structured follow-up protocols. They will maintain compliance with national regulatory guidelines.
Leaders from both sides emphasised patient-centric innovation. They aim to deliver treatments grounded in scientific validation. The collaboration reflects growing convergence between technology and aesthetic medicine.
Industry–academia partnerships now drive modern regenerative healthcare innovation. This initiative signals stronger research ecosystems in India. It supports structured development of next-generation dermatology therapies.
The partnership positions IIT Bombay and QR678 at the forefront of translational skin science. It reinforces India’s expanding footprint in regenerative and aesthetic medicine research.